Anti-Estrogens May Offer Protection Against Lung Cancer Mortality

Main Category: Lung Cancer
Also Included In: Breast Cancer;  Cancer / Oncology
Article Date: 13 Dec 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Anti-estrogens as therapy for breast cancer may also reduce the risk of death from lung cancer, according to study results presented at the CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 9-13, 2009.

"We found a reduction in lung cancer mortality among women treated with anti-estrogens for breast cancer. This work builds on previous studies that had suggested estrogens have a role in lung cancer development and progression," said Elisabetta Rapiti, M.D., M.P.H., medical researcher with the Geneva Cancer Registry, University of Geneva, Switzerland.

Rapiti and colleagues evaluated whether anti-estrogen therapy for breast cancer patients reduced their risk of subsequently developing and/or dying from lung cancer.

The study included 6,715 women living in the Geneva canton of Switzerland who were diagnosed with breast cancer, between 1980 and 2003. Forty-six percent of the women received anti-estrogen therapy, primarily tamoxifen.

By the end of the study period, 40 cases of lung cancer developed. There was no difference in the incidence of lung cancer among women with or without anti-estrogens compared with the general population. However, the risk of dying from lung cancer was significantly lower among women who received anti-estrogen therapy.

"Our results are particularly relevant to the research agenda exploring endocrine treatment(s) for lung cancer," said Rapiti. "If prospective studies confirm our results and find that anti-estrogen agents improve lung cancer outcomes, this could have substantial implications for clinical practice." Phase II clinical trials are currently underway in a number of centers to evaluate the use of anti-hormone therapy as an adjunct to traditional chemotherapy for lung cancer, according to Rapiti.

The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 32nd annual symposium is expected to draw more than 8,500 participants from more than 90 countries.

Source
American Association for Cancer Research (AACR)

• Additional
• References
• Citations